. 2023 Feb 3;12(7):8815–8824. doi: 10.1002/cam4.5626

TABLE 6.

Clinical characteristics of 10 cases of MF breast cancer with different molecular subtypes.

Case	Focus	Diameter (mm)	Histology	Histological grade	ER	PR	HER‐2	KI‐67 (%)	Molecular subtype	Multiplicity
Case1	7	8,6,6,6,6,4,3	IDC ^a	III ^a	(−)	(−)	(+)	50	Her‐2	MF
Case1	7	8,6,6,6,6,4,3	IDC ^a	III ^a	(+)	(−)	(+)	40	Luminal B (HER‐2+)	MF
Case2	2	20,12	IDC	III ^a	(+)	(+)	(+)	50	Luminal B (HER‐2+)	MF
Case2	2	20,12	IDC + DCIS ^b	III ^a	(−)	(−)	(+)	50	HER‐2	MF
Case3	3	30,15	IDC + DCIS	III	(+)	(+)	(−)	40	LuminalB	MF
Case3	3	30,15	Intraductal papillary carcinoma+DCIS ^b	II ^b	(+)	(+)	(−)	12	LuminalA	MF
Case4	2	20,18	IDC + DCIS ^a	III ^a	(+)	(−)	(+)	50	HER‐2	MF
Case4	2	20,18	IDC + DCIS ^a	III ^a	(−)	(−)	(+)	60	Luminal B (HER‐2+)	MF
Case5	2	25,8	IDC ^a	III ^a	(−)	(−)	(−)	80	Triple negative	MF
Case5	2	25,8	IDC ^a	III ^a	(+)	(−)	(−)	60	LuminalB	MF
Case6	2	20,5	IDC + DCIS ^a	III ^a	(+)	(+)	(−)	15	LuminalB	MF
Case6	2	20,5	IDC + DCIS ^a	III ^a	(+)	(+)	(−)	8	LuminalA	MF
Case7	2	26,2	IDC + DCIS ^a	II ^a	(+)	(+)	(−)	40	LuminalB	MF
Case7	2	26,2	IDC + DCIS ^a	II ^a	(−)	(−)	(−)	50	Triple negative	MF
Case8	2	30,15	IDC + DCIS ^a	III ^a	(+)	(−)	(+)	30	LuminalB (HER‐2+)	MF
Case8	2	30,15	IDC + DCIS ^a	III ^a	(−)	(−)	(+)	30	HER‐2	MF
Case9	3	30,15,10	IDC ^a	III ^a	(−)	(−)	(−)	60	Triple negative	MC
Case9	3	30,15,10	IDC ^a	III ^a	(−)	(−)	(+)	70	HER‐2	MC
Case10	2	13,12	Intracystic papillary carcinoma	III ^a	(+)	(+)	(−)	10	LuminalA	MC
Case10	2	13,12	IDC ^b	III ^a	(+)	(+)	(−)	20	LuminalB	MC

^{^a}

Same.

^{^b}

Different.